MPLT Reports $453.1M Cash, $64.6M Q4 R&D, Phase 2 ZEPHYR Enrollment April 2026, ML-007C-MA Fast Track Alzheimer’s, ML-055 Candidate Nomination 2026
MapLight Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $29.76
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS